Exosomes as prognostic biomarkers in pancreatic ductal adenocarcinoma—a systematic review and meta-analysis
Open Access
- 20 January 2022
- journal article
- review article
- Published by Elsevier in Translational Research
- Vol. 244, 126-136
Abstract
No abstract availableKeywords
Funding Information
- Innovációs és Technológiai Minisztérium
- European Commission
- Magyar Tudományos Akadémia (FK131864, K131996, KA–2019–14)
- European Regional Development Fund
- Nemzeti Kutatási, Fejlesztési és Innovaciós Alap
This publication has 39 references indexed in Scilit:
- Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal AdenocarcinomaClinical Chemistry, 2018
- Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced CancersClinical Cancer Research, 2018
- Usefulness of exosome‐encapsulated microRNA‐451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinomaJournal of Hepato-Biliary-Pancreatic Sciences, 2017
- Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2017
- Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline SummaryJournal of Oncology Practice, 2017
- High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patientsAnnals of Oncology, 2017
- Glypican-1 identifies cancer exosomes and detects early pancreatic cancerNature, 2015
- Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liverNature Cell Biology, 2015
- Assessing Bias in Studies of Prognostic FactorsAnnals of Internal Medicine, 2013
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986